EUVIMEDEUVIMED entdecken
Crossref

Pharmacogenetic Testing for Predicting Methylphenidate Treatment Outcomes in Childhood Attention Deficit Hyperactivity Disorder in Turkey: Focus on Carboxylesterase 1, Latrophilin‐3, and Catechol‐O‐Methyltransferase

Ipek Suzer Gamli iD, Anne Van Veggel, Rabia Sevcan Karaaslan iD, Ajla Hodzic Kuerec iD, Zeina Marzoukah iD, Ibrahim Adak iD, Gulay Bulut iD, Huseyin Tunc iD, Candan Perry Hizel, Cuneyd Parlayan iD, Ozalp Ekinci iD, Ron Van Schaik iD und 1 weitere

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · 2025

DOI: 10.1002/ajmg.b.33024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2025. Verfasst von Ipek Suzer Gamli und 12 weiteren Autor:innen. Beteiligte Einrichtung: Child and Adolescent Psychiatry Specialist, Istanbul Erenkoy Mental and Neurological Diseases Training and Research Hospital, Child and Adolescent Ps…. Hauptthemen laut MEDLINE: Methylphenidate, Attention Deficit Disorder with Hyperactivity, Catechol O-Methyltransferase, Carboxylic Ester Hydrolases. Die Arbeit nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacogenetic studies involving Carboxylesterase 1 (CES1), Latrophilin‐3 (LPHN3), and Catechol‐O‐methyltransferase (COMT) revealed individual differences regarding therapeutic response in children with attention deficit hyperactivity disorder (ADHD) under methylphenidate (MPH) treatment. This study aimed to evaluate MPH's association with the adverse effect status in children and its relationship with CES1, LPHN3, and COMT in the Turkish population. The study included 102 children and adolescents with ADHD, who were categorized as responders, or the adverse effect group based on their treatment response. The Naranjo Adverse Drug Reaction Probability Scale evaluated the presence and severity of adverse effects. Saliva sample was taken from the patients and genotype distribution of CES1 rs3815583, CES1 rs2307227, LPHN3 rs6551665, LPHN3 rs1947274, LPHN3 rs6858066, LPHN3 rs2345039, and COMT rs4680 were examined. In the adverse effect group, instances of carrying the GG genotype in CES1 rs2307227, having G vs. T genotype and GG vs. GT were significantly higher. In LPHN3 rs2345039, carrying the C genotype vs. G was associated with a serious adverse effect. In COMT rs4680, individuals with the AA or GG genotype were significantly higher in the adverse effect group. Our study suggests a relationship between genetic polymorphisms and the side effect status in children receiving MPH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethylphenidateAttention Deficit Disorder with HyperactivityCatechol O-MethyltransferaseCarboxylic Ester HydrolasesReceptors, G-Protein-CoupledHumansMaleFemaleChildTurkeyAdolescentPharmacogenomic TestingTreatment OutcomePolymorphism, Single NucleotideGenotypeCarboxylesterasePharmacogeneticsReceptors, Peptide

Stichwörter der Autor:innen

ADHDadverse effectmethylphenidatepharmacogenomics

Substanzen

MethylphenidateCatechol O-MethyltransferaseCarboxylic Ester HydrolasesCES1 protein, humanCOMT protein, humanReceptors, G-Protein-CoupledADGRL3 protein, humanCarboxylesteraseReceptors, Peptide

Autor:innen und Institutionen

  • Child and Adolescent Psychiatry Specialist, Istanbul Erenkoy Mental and Neurological Diseases Training and Research Hospital, Child and Adolescent Psychiatry Unit, Istanbul, Turkey.
  • Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Healthy Longevity Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Queenstown, Singapore.
  • Bahcesehir Unıversity, Graduate School of Health Science, Istanbul, Turkey.
  • Department of Medical Biology, Karabuk University, Faculty of Medicine, Istanbul, Turkey.
  • Bahcesehir University, Faculty of Medicine, Department of Biostatistics and Medical Informatics, Istanbul, Turkey.

ORCID-Profile: Ipek Suzer Gamli, Rabia Sevcan Karaaslan, Ajla Hodzic Kuerec, Zeina Marzoukah, Ibrahim Adak, Gulay Bulut, Huseyin Tunc, Cuneyd Parlayan, Ozalp Ekinci, Ron Van Schaik, Demet Akin

Zitieren

APA

Suzer Gamli, I., Van Veggel, A., Karaaslan, R. S., Kuerec, A. H., Marzoukah, Z., Adak, I., Bulut, G., Tunc, H., Hizel, C. P., Parlayan, C., Ekinci, O., Van Schaik, R., & Akin, D. (2025). Pharmacogenetic Testing for Predicting Methylphenidate Treatment Outcomes in Childhood Attention Deficit Hyperactivity Disorder in Turkey: Focus on Carboxylesterase 1, Latrophilin‐3, and Catechol‐O‐Methyltransferase. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. https://doi.org/10.1002/ajmg.b.33024

Vancouver

Suzer Gamli I, Van Veggel A, Karaaslan RS, Kuerec AH, Marzoukah Z, Adak I, et al. Pharmacogenetic Testing for Predicting Methylphenidate Treatment Outcomes in Childhood Attention Deficit Hyperactivity Disorder in Turkey: Focus on Carboxylesterase 1, Latrophilin‐3, and Catechol‐O‐Methyltransferase. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2025. doi:10.1002/ajmg.b.33024

BibTeX
@article{SuzerGamli2025,
  author = {Suzer Gamli, Ipek and Van Veggel, Anne and Karaaslan, Rabia Sevcan and Kuerec, Ajla Hodzic and Marzoukah, Zeina and Adak, Ibrahim and Bulut, Gulay and Tunc, Huseyin and Hizel, Candan Perry and Parlayan, Cuneyd and Ekinci, Ozalp and Van Schaik, Ron and Akin, Demet},
  title = {Pharmacogenetic Testing for Predicting Methylphenidate Treatment Outcomes in Childhood Attention Deficit Hyperactivity Disorder in Turkey: Focus on Carboxylesterase 1, Latrophilin‐3, and Catechol‐O‐Methyltransferase},
  journal = {American Journal of Medical Genetics Part B: Neuropsychiatric Genetics},
  year = {2025},
  doi = {10.1002/ajmg.b.33024}
}
Kostenlos starten →